Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Bausch Health Companies Inc.

SG&A Expenses: Alnylam vs. Bausch Health (2014-2023)

__timestampAlnylam Pharmaceuticals, Inc.Bausch Health Companies Inc.
Wednesday, January 1, 2014445260002026300000
Thursday, January 1, 2015606100002682700000
Friday, January 1, 2016893540002810000000
Sunday, January 1, 20171993650002582000000
Monday, January 1, 20183823590002473000000
Tuesday, January 1, 20194790050002554000000
Wednesday, January 1, 20205884200002367000000
Friday, January 1, 20216206390002624000000
Saturday, January 1, 20227706580002625000000
Sunday, January 1, 20237956460002917000000
Monday, January 1, 2024975526000
Loading chart...

Unlocking the unknown

Cost Management Insights: SG&A Expenses Analysis

In the competitive landscape of pharmaceuticals, effective cost management is crucial. Alnylam Pharmaceuticals, Inc. and Bausch Health Companies Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting its aggressive growth and expansion strategy. In contrast, Bausch Health maintained a more stable trajectory, with expenses fluctuating around a 44% range, peaking in 2023. This divergence highlights Alnylam's investment in scaling operations, while Bausch Health focuses on optimizing existing resources. Understanding these trends provides valuable insights into each company's strategic priorities and financial health. As the industry evolves, monitoring such financial metrics will be key to predicting future market leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025